Analysis of efficacy and safety of POM as a replacement therapy for ...

The median PFS for the cohort was 7.6 months. Common ≥ Gr3 adverse events were neutropenia (8%), hypomania (4%) and leukopenia (4%). Conclusions: We show ...

Efficacy and safety of pomalidomide as a replacement therapy for ...

Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of ...

Efficacy and Safety of Pomalidomide As a Replacement Therapy for ...

Pomalidomide (POM) is an immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) ...

Analysis of efficacy and safety of POM as a replacement therapy for ...

Request PDF | Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory to a ...

Efficacy and safety of generic pomalidomide plus low-dose ...

This study reaffirmed that RRMM patients with ISS stage I/R-ISS stage I benefited the most from POM + LD-Dex treatment. Moreover, POM + LD-Dex ...

Efficacy and safety of generic pomalidomide plus low-dose ... - NCBI

This study reaffirmed that RRMM patients with ISS stage I/R-ISS stage I benefited the most from POM + LD-Dex treatment. Moreover, POM + LD-Dex ...

Safety and efficacy of pomalidomide plus low-dose dexamethasone ...

In the randomized MM-002 study, overall response rate (ORR; ≥ partial response [PR]) was significantly higher with pomalidomide plus low-dose ...

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients ...

Rates of peripheral neuropathy and venous thromboembolism were low (≤ 5%). Among the 38 patients enrolled (including 22 with added dexamethasone) ...

Tolerability and safety of real‑world use of pomalidomide in patients ...

The most frequent treatment dose was 3 mg/day. POM dose reductions were required in 54.5% (6/11) of the patients. The patient data were compared ...

Clinical outcomes of pomalidomide‐based and daratumumab ...

This retrospective study reports the efficacy and safety of Pom-based, Dara-based, and DPd regimens for patients with RRMM in a single Chinese ...

Safety and efficacy of pomalidomide, dexamethasone and pegylated ...

POM, PLD and DEX is a treatment option for relapsed/refractory MM patients including those who are refractory to LEN, and the combination of POM with DEX 40 ...

A phase 3 trial comparing the efficacy and safety of pomalidomide ...

... Recently, a randomized phase 2 study reported a higher response rate (65% versus 39%, P = 0.035) and superior median PFS (9.5 months ...

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy ...

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide ...

Clinical efficacy of daratumumab, pomalidomide, and ...

The results of this retrospective analysis highlight the safety and efficacy of the DARA-POM-D regimen in treating patients with RRMM who ...

Safety and efficacy of pomalidomide plus low-dose dexamethasone ...

... new safety signals emerging, and was not significantly different between patients receiving POM/ LoDex in the third versus later line of therapy. Expand. 3 ...

dreamm 2 - Cancer Trial Results

Longer-term follow-up found a median duration of response of around 11 months for the 2.5mgs/kg cohort. Subset analysis revealed that the number of prior lines ...

A study on the safety and efficacy of reveglucosidase alfa in patients ...

Current enzyme replacement therapy with recombinant human (rh)GAA has demonstrated efficacy in subjects with late-onset Pompe disease. However, ...

Efficacy and safety of enzyme replacement therapy with ... - Frontiers

Meta-analysis suggests that the effect of ERT is potentially beneficial in patients' survival. However, there is uncertainty due to high statistical ...

Program Guide – ASCO Meeting Program Guide

Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory ...

Search for Pompe Disease - Clinical Trials register

Full Title: An Open-Label, Multicenter, Multinational Extension Study Of The Long-Term Safety And Pharmacokinetics Of Repeated Biweekly Infusions Of ...